492 related articles for article (PubMed ID: 11517156)
1. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor.
Huber DM; Bendixen AC; Pathrose P; Srivastava S; Dienger KM; Shevde NK; Pike JW
Endocrinology; 2001 Sep; 142(9):3800-8. PubMed ID: 11517156
[TBL] [Abstract][Full Text] [Related]
2. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
3. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
4. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
5. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
[TBL] [Abstract][Full Text] [Related]
6. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression.
Shevde NK; Bendixen AC; Dienger KM; Pike JW
Proc Natl Acad Sci U S A; 2000 Jul; 97(14):7829-34. PubMed ID: 10869427
[TBL] [Abstract][Full Text] [Related]
7. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA
Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985
[TBL] [Abstract][Full Text] [Related]
8. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
[TBL] [Abstract][Full Text] [Related]
9. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
10. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage.
Khapli SM; Mangashetti LS; Yogesha SD; Wani MR
J Immunol; 2003 Jul; 171(1):142-51. PubMed ID: 12816992
[TBL] [Abstract][Full Text] [Related]
11. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
12. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
[TBL] [Abstract][Full Text] [Related]
13. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation.
Ikeda F; Nishimura R; Matsubara T; Tanaka S; Inoue J; Reddy SV; Hata K; Yamashita K; Hiraga T; Watanabe T; Kukita T; Yoshioka K; Rao A; Yoneda T
J Clin Invest; 2004 Aug; 114(4):475-84. PubMed ID: 15314684
[TBL] [Abstract][Full Text] [Related]
14. Lipopolysaccharide-induced osteoclastogenesis in Src homology 2-domain phosphatase-1-deficient viable motheaten mice.
Hayashi S; Tsuneto M; Yamada T; Nose M; Yoshino M; Shultz LD; Yamazaki H
Endocrinology; 2004 Jun; 145(6):2721-9. PubMed ID: 14988381
[TBL] [Abstract][Full Text] [Related]
15. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
[TBL] [Abstract][Full Text] [Related]
16. Possible involvement of protein kinases and Smad2 signaling pathways on osteoclast differentiation enhanced by activin A.
Murase Y; Okahashi N; Koseki T; Itoh K; Udagawa N; Hashimoto O; Sugino H; Noguchi T; Nishihara T
J Cell Physiol; 2001 Aug; 188(2):236-42. PubMed ID: 11424090
[TBL] [Abstract][Full Text] [Related]
17. Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation.
Park EK; Kim MS; Lee SH; Kim KH; Park JY; Kim TH; Lee IS; Woo JT; Jung JC; Shin HI; Choi JY; Kim SY
Biochem Biophys Res Commun; 2004 Dec; 325(4):1472-80. PubMed ID: 15555594
[TBL] [Abstract][Full Text] [Related]
18. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
[TBL] [Abstract][Full Text] [Related]
19. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
20. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
